Trials / Active Not Recruiting
Active Not RecruitingNCT06041386
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
A Prospective, Real-World, Interventional Study To Evaluate The Effect Of Mepolizumab On Achieving Clinical Remission In Participants With Severe Asthma
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 336 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mepolizumab | Mepolizumab will be prescribed based on physician decision. |
| OTHER | Spirometry | Lung function via spirometry will be collected. |
Timeline
- Start date
- 2024-03-20
- Primary completion
- 2025-01-31
- Completion
- 2028-06-14
- First posted
- 2023-09-18
- Last updated
- 2025-08-01
Locations
65 sites across 9 countries: United States, Belgium, Canada, France, Germany, Italy, Japan, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06041386. Inclusion in this directory is not an endorsement.